Video Experimental Relacionado
Updated: Feb 22, 2026
12:35
In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion
Published on: November 10, 2011
19.7K
Priming de la vía endocítica del hígado para acelerar la depuración hepatobiliar de las nanopartículas
Yunfeng Ren1, Fang Mei1, Huixu Lu1
1School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P.R. China.
ACS nano
|February 21, 2026
Resumen
Priming el hígado para inhibir la endocitosis mediada por clatrina (CME) acelera la eliminación de nanopartículas. Esta estrategia mejora la exocitosis de las células hepáticas, reduciendo la acumulación de nanopartículas y mejorando la administración de nanomedicina.
Área de la Ciencia:
- Nanotecnología La nanotecnología es la nanotecnología.
- Ciencias hepáticas y biliares Ciencias hepáticas y biliares
- Entrega de drogas Envío de drogas
Sus antecedentes:
- La acumulación prolongada en el hígado de nanomedicinas dificulta el uso clínico, especialmente para las nanopartículas no biodegradables.
- Las estrategias actuales se centran en reducir la absorción hepática, y pocas abordan la eliminación acelerada después de la absorción.
Objetivo del estudio:
- Desarrollar una estrategia de amplia aplicación para acelerar la eliminación hepatobiliar de nanopartículas.
- Para investigar el papel de las vías endocíticas del hígado en el aclaramiento de nanopartículas.
Principales métodos:
- La inhibición de la endocitosis mediada por clatrina (CME) mediante el uso de clorpromazina en ratones.
- Evaluación del tráfico intracelular de nanopartículas y la exocitosis de los hepatocitos y los macrófagos.
- Evaluación del aclaramiento hepatobiliar y la retención hepática de diversas nanopartículas.
- Pruebas en un modelo de tumor murino para evaluar la eficacia de la administración de nanomedicina.
Principales resultados:
- La inhibición de la CME mejoró significativamente la exocitosis de nanopartículas de los hepatocitos y los macrófagos.
- El tráfico intracelular alterado desvió las nanopartículas al Golgi para una exocitosis más rápida.
- El primeramiento con clorpromazina aceleró el aclaramiento hepatobiliar y redujo la retención hepática de varias nanopartículas.
- La inhibición de la EMC hepática aceleró la eliminación sin comprometer la eficacia de la orientación tumoral.
Conclusiones:
- Iniciar la vía endocítica hepática a través de la inhibición de la CME es una estrategia versátil para acelerar la eliminación de nanopartículas.
- Este enfoque ofrece una estrategia complementaria a los métodos existentes para reducir la acumulación hepática de nanomedicinas.
Videos de Conceptos Relacionados
01:14Hepatic Drug Clearance: Role of Transporters
335
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
335
01:23Drug Elimination: Non-Renal Routes
3.4K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
3.4K
01:17Hepatic Drug Excretion: Enterohepatic Cycling
3.0K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.0K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
337
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
337
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
272
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
272
01:27Bioavailability Enhancement: Drug Permeability Enhancement
248
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
248